Picture of Neuronetics logo

STIM Neuronetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Neuronetics Inc reports results for the quarter ended in March - Earnings Summary

* Neuronetics Inc  STIM.OQ  reported a quarterly adjusted
loss
of 27 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -38 cents.  The mean expectation of four analysts for the
quarter was for a loss of 31 cents per share. Wall Street
expected results to range from -37 cents to -26 cents per share.
    * Revenue rose 12.1% to $17.42 million from a year ago;
analysts
expected $17.12 million. 
    * Neuronetics Inc's reported EPS for the quarter was a loss
of 27
cents​.
    * The company reported a quarterly loss of $7.87 million.
    * Neuronetics Inc shares had fallen by 21.2% this
quarter and
gained 29.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 5.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Neuronetics
Inc
is $7.00 

This summary was machine generated from LSEG data May 7 at 02:23
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.31          -0.27          Beat
 Dec. 31 2023      -0.26          -0.19          Beat
 Sep. 30 2023      -0.31          -0.33          Missed
 Jun. 30 2023      -0.35          -0.17          Beat

Recent news on Neuronetics

See all news